Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
22nd Century Group Inc (XXII)
22nd Century Group Inc (XXII)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,183
  • Shares Outstanding, K 30,878
  • Annual Sales, $ 62,110 K
  • Annual Income, $ -59,800 K
  • 60-Month Beta 1.59
  • Price/Sales 0.13
  • Price/Cash Flow N/A
  • Price/Book 0.46
Trade XXII with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.18
  • Most Recent Earnings -0.78 on 11/06/23
  • Next Earnings Date 11/14/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 333.90% ( -26.09%)
  • Historical Volatility 148.85%
  • IV Percentile 94%
  • IV Rank 39.44%
  • IV High 792.91% on 11/27/23
  • IV Low 34.91% on 04/12/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 71
  • Volume Avg (30-Day) 257
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 68,085
  • Open Int (30-Day) 69,080

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.66
  • Number of Estimates 3
  • High Estimate -0.47
  • Low Estimate -0.82
  • Prior Year -1.80
  • Growth Rate Est. (year over year) +63.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2010 +31.84%
on 11/28/23
0.5395 -50.88%
on 11/06/23
-0.1673 (-38.70%)
since 11/01/23
3-Month
0.2010 +31.84%
on 11/28/23
1.6896 -84.32%
on 09/05/23
-0.9950 (-78.97%)
since 09/01/23
52-Week
0.2010 +31.84%
on 11/28/23
18.9750 -98.60%
on 01/18/23
-17.2850 (-98.49%)
since 12/01/22

Most Recent Stories

More News
Stock Index Futures Slip Ahead of Key U.S. Retail Sales Data, U.S. Bank Earnings on Tap

December S&P 500 futures (ESZ23) are down -0.26%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.27% this morning as investors geared up for quarterly reports from more big banks and industry...

ESZ23 : 4,600.75s (+0.52%)
NQZ23 : 16,023.75s (+0.24%)
SCHW : 63.16 (+3.00%)
LULU : 466.61 (+4.43%)
MSFT : 374.51 (-1.16%)
JNJ : 158.38 (+2.41%)
BAC : 30.96 (+1.54%)
LMT : 449.41 (+0.37%)
GS : 348.43 (+2.02%)
PLD : 118.26 (+2.90%)
UAL : 40.24 (+2.13%)
ERICB.S.DX : 51.940 (-0.03%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 22nd Century Group, Inc. - XXII

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 22nd Century Group, Inc. ("22nd Century" or the "Company") (NASDAQ: XXII). Such...

XXII : 0.2650 (+1.92%)
22nd Century Group (XXII) Q2 2023 Earnings Call Transcript

XXII earnings call for the period ending June 30, 2023.

XXII : 0.2650 (+1.92%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 22nd Century Group, Inc. - XXII

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 22nd Century Group, Inc. ("22nd Century" or the "Company") (NASDAQ: XXII). Such...

XXII : 0.2650 (+1.92%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 22nd Century Group, Inc. - XXII

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 22nd Century Group, Inc. ("22nd Century" or the "Company") (NASDAQ: XXII). Such...

XXII : 0.2650 (+1.92%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 22nd Century Group, Inc. - XXII

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 22nd Century Group, Inc. ("22nd Century" or the "Company") (NASDAQ: XXII). Such...

XXII : 0.2650 (+1.92%)
Global E-Cigarette Market Estimated to Grow to $168 Billion by 2030

EQNX::TICKER_START (NASDAQ:XXII),(NYSE:BTI),(NYSE:MO),(NYSE:PM),(OTCQX:IMBBY) EQNX::TICKER_END

MO : 42.60 (+1.33%)
XXII : 0.2650 (+1.92%)
BTI : 32.04 (+0.47%)
PM : 94.05 (+0.74%)
IMBBY : 24.1600 (+1.94%)
Global E-Cigarette Market Estimated to Grow to $168 Billion by 2030

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Around the world, people are becoming more aware of the hazardous effects of regular smoking...

XXII : 0.2650 (+1.92%)
BTI : 32.04 (+0.47%)
MO : 42.60 (+1.33%)
PM : 94.05 (+0.74%)
IMBBY : 24.1600 (+1.94%)
3 Biotech Stocks Losing Market Value

There is a growing demand for healthcare solutions, and the biotech industry will likely benefit from it. However, not all biotech stocks are well-positioned to capitalize on the industry tailwinds. Therefore,...

BCYC : 14.99 (+4.10%)
CRMD : 3.35 (+3.08%)
XXII : 0.2650 (+1.92%)
22nd Century Group (XXII) Q1 2023 Earnings Call Transcript

XXII earnings call for the period ending March 31, 2023.

XXII : 0.2650 (+1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products...

See More

Key Turning Points

3rd Resistance Point 0.3267
2nd Resistance Point 0.2963
1st Resistance Point 0.2807
Last Price 0.2650
1st Support Level 0.2347
2nd Support Level 0.2043
3rd Support Level 0.1887

See More

52-Week High 18.9750
Fibonacci 61.8% 11.8033
Fibonacci 50% 9.5880
Fibonacci 38.2% 7.3727
Last Price 0.2650
52-Week Low 0.2010

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar